免疫衰老分子标志在肿瘤发生发展和免疫检查点抑制剂治疗中的研究进展  

Research progress on molecular markers of immunosenescence in tumor development and immune checkpoint inhibitor therapy

作　　者：李文頔 肖琳 崔巍 Li Wendi;Xiao Lin;Cui Wei(Department of Clinical Laboratory,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing100021,China)

机构地区：[1]国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院检验科,北京100021

出　　处：《中华检验医学杂志》2024年第12期1487-1492,共6页Chinese Journal of Laboratory Medicine

基　　金：北京市自然科学基金(L244031)。

摘　　要：免疫检查点抑制剂(ICI)为肿瘤治疗带来了突破性进展,但较低的治疗响应率仍然是重要挑战,亟需有效的生物标志物用于免疫治疗的监测。免疫衰老通过降低机体免疫监视能力促进肿瘤发生发展,在肿瘤进展和免疫治疗中发挥关键作用。随着流式细胞术、多组学分析和单细胞技术等方法的应用,免疫衰老分子标志检测在肿瘤风险评估、预后预测及ICI疗效监测中取得重要进展。Immune checkpoint inhibitors(ICI)have brought breakthrough advancements to cancer therapy.However,the relatively low treatment response rate remains a significant challenge,highlighting the urgent need for effective laboratory biomarkers to monitor immunotherapy.Immunosenescence promotes tumor initiation and progression by reducing the immune surveillance capability of the body and plays a critical role in tumor progression and immunotherapy.With the application of techniques such as flow cytometry,multi-omics analysis,and single-cell technology,the detection of immunosenescence molecular markers has made significant progress in tumor risk assessment,prognosis prediction,and ICI efficacy monitoring.

关 键 词：免疫 衰老 分子标志 肿瘤 免疫检查点抑制剂 

分 类 号：R730[医药卫生—肿瘤]